Bioqual(OTC) BIOQ

Bioqual, Inc. is a leading provider of preclinical research solutions, specializing in both in-vivo and in-vitro methodologies. The company serves a diverse clientele, including commercial enterprises and government agencies, focusing on critical health domains such as COVID-19, AIDS, and various viral infections.

Products and Services

• Preclinical research solutions for various health domains
• Advanced laboratory capabilities, including biological sample processing
• Support for studies utilizing animal research models

Growth Outlook

• Revenue of $9.84 million in the latest quarter, showing resilience
• Strong cash position with $11.26 million in cash and equivalents
• Current ratio of 4.01 indicates robust liquidity

Financial Highlights

• Trailing twelve months (TTM) revenue of $39.5 million
• Net income of -$752,524 in the latest quarter, reflecting ongoing investments
• Operating cash flow of $1.2 million in the latest quarter, indicating operational efficiency

Bioqual, Inc. has established itself as a key player in the medical diagnostics and research industry. The company's focus on preclinical research solutions positions it well to capitalize on the growing demand for innovative health solutions. With a strong cash position and a solid current ratio, Bioqual demonstrates financial stability, which is crucial for navigating the competitive landscape. The recent quarterly revenue figures reflect the company's ability to maintain operations despite challenges, while the operating cash flow indicates effective management of resources. Overall, Bioqual, Inc. presents a compelling opportunity for investors interested in the healthcare sector.